Narnatumab

Narnatumab (IMC-RON8) is a humanized antibody that targets the macrophage-stimulating receptor 1 (RON). Narnatumab blocks the binding of RON to its ligand, macrophage-stimulating protein (MSP), and inhibits receptor activation, thereby suppressing tumor cell proliferation and migration. It is being investigated for the treatment of advanced malignant solid tumors.

RON:32 pM (Kd)

Narnatumab is a fully humanized monoclonal antibody that binds with high affinity to RON, thereby preventing RON from binding to HGFL. [1]
Methods: RON-positive lung, breast, and pancreatic cancer cell lines were selected and treated with Narnatumab (1–10 μg/mL) for 24–72 h. MSP-induced cell migration, proliferation, and phosphorylation levels in downstream signaling pathways were then assessed.
Results: Narnatumab binds to RON with high affinity (Kd = 32 pM), blocks the binding of MSP to RON, inhibits downstream signaling activation, and significantly reduces the migration and proliferation capabilities of tumor cells.[2]

Methods: Xenograft models of colorectal, lung, pancreatic, and breast cancer were established in nude mice. Narnatumab (10–30 mg/kg) was administered intravenously twice weekly for 2–4 weeks, and tumor volume was monitored using a caliper.
Results: Narnatumab significantly inhibited the growth of multiple tumors. Its half-life in mice was 5.2 days, and the minimum effective concentration for tumor suppression was approximately 140 μg/mL. [2]

Human

Monoclonal

Unconjugated